ClinicalTrials.gg
RecruitingNCT07220239SCREEN-CUPUpdated Jun 10, 2026

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome

An interventional study of Menstrual cup use in Endometrial Cancer, Lynch Syndrome and Screening, sponsored by Jessica D. St. Laurent, MD. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Jessica D. St. Laurent, MD · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Planned enrollment
445th of 591
25 · median 60
Started
2025
with 54 others
No phase
116 of 715
29 open now
Primary completion
2027-03
later than 96 of 283 live
Registered
651st of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 445th largest by planned enrollment of the 591 interventional ones that give a count, is one of 55 that started in 2025, is one of 116 with no phase, reaches primary completion later than 96 of the 283 other live ones, and was the 651st registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

190 more — sign in →

All 195 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Study Goal:

This pilot study wants to find out if using a menstrual cup can be a good, non-invasive way to collect samples from the lining of the uterus (called the endometrium) to help screen for endometrial cancer. This is especially important for women who have a higher chance of getting this cancer, such as those with a genetic condition called Lynch syndrome.

Main Questions the Study Will Answer:

  1. Can a menstrual cup collect enough uterine lining (endometrial tissue) for doctors to examine under a microscope?
  2. Are the samples from the menstrual cup as useful for diagnosis as samples taken using the usual method (called an endometrial biopsy or EMB)?
  3. Is using a menstrual cup at home easy, effective, and comfortable for participants?
  4. Can scientists grow small lab models of the uterus (called organoids) from the menstrual cup samples and from biopsy samples?

What Will Happen in the Study:

  • Participants will use a menstrual cup at home to collect menstrual blood.
  • They will also have a standard endometrial biopsy done by a healthcare provider.
  • After both collections, participants will fill out a short survey about how comfortable and easy it was to use the menstrual cup.

What the Study Will Measure:

  • Feasibility: How well participants are able to use the menstrual cup and send in the sample.
  • Sample Quality: Whether the menstrual cup collects enough good-quality tissue for testing, and how it compares to biopsy samples.
  • Participant Experience: How women feel about using the menstrual cup, based on the survey.
  • Lab Testing: Whether researchers can successfully grow endometrial organoids from both types of samples.

Why This Study Matters: If this method works, it could offer a gentler, more convenient way for women to get checked for endometrial cancer-especially those who need regular screening. It could also make it easier to collect samples for research and improve early detection of cancer.

Read the detailed description

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome (SCREEN-CUP) The study entails two parts that will be conducted one after each other.

  1. Pre-pilot study Pre-pilot study including 5 menstruating females who will provide a one-time menstrual cup-based endometrial collection for the generation of organoids and for a pathological evaluation of endometrial specimen from menstrual fluid.

    After optimizing the study protocol in the pre-pilot study period, the main study will be conducted.

  2. Main pilot study Prospective feasibility study including 20 female Lynch syndrome (LS) carriers undergoing annual endometrial biopsy for endometrial cancer surveillance or suspected endometrial pathology will provide a one-time menstrual cup-based endometrial collection and endometrial biopsy specimen. One study aim is to evaluate the comparability and quality of the menstrual cup-based endometrial collection with the EMB sample from the same patient. For the second study aim, endometrial sample collected with the menstrual cup and EMB will be used and compared for organoid generation. Patient satisfaction and feasibility will be monitored through patient and provider questionnaires.
03

Conditions studied

  • Endometrial Cancer
  • Lynch Syndrome
  • Screening
  • Early Detection of Cancer

Keywords

  • Endometrial Cancer
  • Lynch Syndrome
  • Screening
  • Early detection
  • Organoids
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Pre-pilot study

Inclusion criteria:

  • Individuals over the age of 18
  • Menstruating

Exclusion criteria:

  • Levonorgestrel intrauterine device (IUD) in situ or removed within the last 30 days prior to sample collection
  • Patients with prior endometrial ablation
  • Prior history of endometrial cancer or endometrial intraepithelial neoplasia
  • History of germline pathologic germline variant in MLH1, MSH2, MSH6, PMS2, or EPCAM
  • Known allergy against menstrual cup material (silicone)

Main Study Inclusion criteria

  • LS carrier with a pathogenic or likely pathogenic germline variant in MLH1, MSH2, MSH6, PMS2, or EPCAM
  • Individuals over the age of 18
  • Planned screening EMB
  • Menstruating
  • Ability to give consent

Exclusion criteria:

  • Current pregnancy
  • Levonorgestrel IUD in situ or removed within the last 30 days prior to sample collection
  • Patients with prior endometrial ablation
  • Prior history of endometrial cancer
  • Known allergy against menstrual cup material (silicone)
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Other
    Pilot study arm

    Single arm study: Intervention includes use of a mentrual cup to collect menstrual fluid

    Device: Menstrual cup use

Interventions

  • DeviceMenstrual cup use

    Menstrual cup use in menstruating women to collect menstrual fluid with the aim to 1) compare the histology to endometrial biopsy samples from the same patient, to 2) investigate the feasibility and clinical utility of a menstrual cup use as a screening method for endometrial cancer and to 3) generate organoids from the menstrual cup samples

06

What researchers measure

Primary outcomes

  1. Proportion of samples considered adequate for pathologic evaluation

    A pathologist will evaluate the menstrual cup-based sample and record its adequacy for pathological evaluation using a questionnaire with binary responses.

    Time frame: Postprocedural (7-14 days after study visit #2)

Secondary outcomes

  1. Overall participant satisfaction with menstrual cup collection for endometrial screening.

    Participants self-report to questions on overall participant satisfaction with menstrual cup collection for endometrial screening with 5 answer possibilities ranging from "very satisfied" to "very dissatisfied".

    Time frame: Periprocedural (on day of study visit #2)

  2. Successful endometrial organoid generation from menstrual cup sample

    Successful organoid generation from menstrual cup samples will be assessed by viability assays after 5 days of culture and immunofluorescence imaging to compare cell composition.

    Time frame: Postprocedural (5-7 days after study visit #2)

  3. Successful endometrial organoid generation from endometrial biopsy sample (EMB).

    Successful organoid generation from EMB samples will be assessed by viability assays after 5 days of culture and immunofluorescence imaging to compare cell composition.

    Time frame: Postprocedural (5-7 days after study visit #2)

  4. Provider satisfaction of menstrual cup collection for endometrial cancer screening within this study setting

    Provider self-report on question regarding satisfaction of menstrual cup collection for endometrial cancer screening within this study setting with 5 answer possiblities ranging from "very satisfied" to "very dissatisfied".

    Time frame: Through study completion, an average of 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cindrova-Davies T, Zhao X, Elder K, Jones CJP, Moffett A, Burton GJ, Turco MY. Menstrual flow as a non-invasive source of endometrial organoids. Commun Biol. 2021 Jun 17;4(1):651. doi: 10.1038/s42003-021-02194-y. PubMed 34140633 ↗
  • Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Canadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3. PubMed 29101162 ↗
  • Hewitt SC, Dickson MJ, Edwards N, Hampton K, Garantziotis S, DeMayo FJ. From cup to dish: how to make and use endometrial organoid and stromal cultures derived from menstrual fluid. Front Endocrinol (Lausanne). 2023 Sep 21;14:1220622. doi: 10.3389/fendo.2023.1220622. eCollection 2023. PubMed 37810883 ↗

Individual participant data

Plan to share: Yes — De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a data use agreement. The protocol and statistical analysis plan will be made available to on clinicaltrials.gov only as required by federal regulations or as a condition of awards and agreements supporting research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 12 months after publication of the primary results, for a period of up to 3 years.

Access criteria: Researchers must submit a methodologically sound proposal and demonstrate an IRB-approved protocol. Requests maybe directed to the sponsor investigator or designee. A formal data use agreement will be required prior to access.

Data sharing details ↗ · www.stlaurentlab.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.

Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 16 months is below that.

Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Oct 23, 2025
StartActual
Nov 20, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07220239
Lead sponsor
Jessica D. St. Laurent, MD
Responsible party
Jessica D. St. Laurent, MD (Director, Gynecologic Oncology Laboratory, Brigham and Women's Hospital) — Sponsor-investigator
First posted
Oct 23, 2025
Start date
Nov 20, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jun 10, 2026

Study contacts

Jessica D St. Laurent, MD
Contact
jdstlaurent@bwh.harvard.edu
857-215-1892
Jessica D St. Laurent, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion